Amarin reported $20.81M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 608K Jun/2026
Alnylam Pharmaceuticals USD 133.88M 141K Sep/2026
Amarin USD 20.81M 13K Dec/2025
AstraZeneca USD 1.55B 28K Sep/2026
BioCryst Pharmaceuticals USD 255.26M 42.2M Jun/2026
DBV Technologies USD 235.6M 98.78M Dec/2025
GlaxoSmithKline GBP 2.02B 2.05B Sep/2026
Halozyme Therapeutics USD 113.94M 106K Sep/2026
Heron Therapeutics USD 188.31M 4.99M Dec/2025
Ionis Pharmaceuticals USD 166.41M 773K Sep/2026
Nektar Therapeutics USD 29.47M 9.09M Mar/2026
Neurocrine Biosciences USD 101.3M 750K Sep/2026
Novartis USD 1.89B 12.09M Sep/2026